drug development

Israeli artificial intelligence startup CytoReason recently announced that it has completed $80 million in financing, with investors including industry giants such as Nvidia, Pfizer, OurCrowd and Thermo Fisher Scientific. The company plans to use the funds to accelerate the development of its AI platform for disease modeling and drug discovery. CytoReason was founded in 2016 and is headquartered in Tel Aviv. The AI platform developed by the company can extract insights from human disease data, create computational disease models for predictive therapies, and assist pharmaceutical researchers in making data-driven decisions. Its core technology is in the fine…